HELP - Cybin D/B/A Helus Pharma News

Helus Pharma Appoints Mark Lawson As Board Chair, Effective Immediately

Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"),

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward

Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus

Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22

Wells Fargo analyst Benjamin Burnett maintains Helus Pharma (NASDAQ:HELP) with a Overweight and r

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2

Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjuncti

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

This news release constitutes a “designated news release” for the purpose of the Company's prospectu

seekingalpha.com

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term c

Helus Pharma to Host Investor Presentation on October 21, 2026

NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: H

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP)

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HL

defenseworld.net

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Cybin (NASDAQ: HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of

Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026

Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-st

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of S

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Mi

Helus Pharma Presents Four Posters Evaluating HLP003 To Treat Major Depressive Disorder At Psych Con

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a cli

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program e

defenseworld.net

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III r

Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an exp

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III r

9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarke

Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6%

defenseworld.net

Insider Buying: Cybin (NASDAQ:HELP) Insider Purchases $1,239,000.00 in Stock

Cybin Inc. (NASDAQ: HELP - Get Free Report) insider Eric So acquired 100,000 shares of the stock in

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential moment

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New Yo

CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m.

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New Y

CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. ED

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. ED

seekingalpha.com

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The comp

TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62

TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price

Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst con

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Sess

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a

Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clin

Wells Fargo Initiates Coverage On Helus Pharma with Overweight Rating, Announces Price Target of $16

Wells Fargo analyst Benjamin Burnett initiates coverage on Helus Pharma (NASDAQ:HELP) with a Over

Crude Oil Surges 2%; 3M Shares Gain After Q2 Results

US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer sta

Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Helus Pharma Completes Enrollment In Its APPROACH Phase 3 Study Of HLP003 In Patients Living With Ma

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramParticipant

Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday

U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, sto

Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7

HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and low

Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst con

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollm

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorde

'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants'

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Helus Pharma CEO Michael Cola Stepping Down, Effective Immediately; Executive Chairman Eric So Appoi

Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to h

TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating an

12 Health Care Stocks Moving In Thursday's Intraday Session

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pr

HC Wainwright & Co. Maintains Buy on Helus Pharma, Raises Price Target to $95

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a B

Helus Pharma Announces Publication In Nature Medicine Of Results From Phase 2a Randomized, Placebo-C

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a cli